Reappraisal of MMR vaccines currently used in Korea

Hyunju Lee, Han Wool Kim, Hye Kyung Cho, Eun Ae Park, Kyong Min Choi, Kyung Hyo Kim

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Background: Although MMR vaccine is widely used in Korea, there are limited studies on the currently used vaccines. We evaluated the immunogenicity and safety of MMR vaccines in Korean children. Methods: For first and second dose immunization, children aged 12-23 months and 4-6 years were enrolled. All subjects received a single dose of either Priorix™ (Glaxo Smithkline Biologicals, Rixensart, Belgium) or MMRII® (Merck & Co., Inc., West Point, PA, USA). Pre- and postvaccine sera were collected from all participants. Antibody levels were determined by ELISA (Enzygnost®; Dade Behring, Schwalbach, Germany). Safety monitoring included local adverse events for 5 days and systemic adverse events for 42 days following vaccination. Results: One hundred twenty-one subjects were enrolled in the 12-23 months age group and 39 in the 4-6 years age group. The seroconversion rate in the 12-23 months age group was 97.9-100.0% for measles, 85.1-88.9% for mumps and 100.0% for rubella. All children 4-6 years of age previously seronegative showed seroconversion for measles, mumps and rubella. Local adverse events were reported in 8.3-16.1% (12-23 months age) and 27.8-31.6% (4-6 years age), and 40.0-48.2% (12-23 months age) and 42.1-61.1% (4-6 years age) experienced at least more than 1 systemic adverse reaction. No vaccine-related serious adverse events were reported. Among the same age groups, there was no significant difference in adverse events between the two vaccines. Conclusion: The MMR vaccines are safe and show good immunogenic responses in children. These data will be invaluable when we introduce diverse vaccines in the following future.

Original languageEnglish
Pages (from-to)374-380
Number of pages7
JournalPediatrics International
Issue number3
StatePublished - Jun 2011


  • measles
  • measles-mumps-rubella vaccine
  • mumps
  • rubella
  • vaccines


Dive into the research topics of 'Reappraisal of MMR vaccines currently used in Korea'. Together they form a unique fingerprint.

Cite this